WUXI BIO's net income decline narrowed to 1.3%, with North America accounting for more than half of the revenue | Interpretations

In 2024, revenue is projected to be 18.675 billion yuan, an increase of 9.6% year-on-year, with a net income of 3.356 billion yuan, a decrease of 1.3% compared to last year. Revenue from North America reached 10.696 billion yuan, growing by 32.48% compared to 2023, accounting for 57.3% of total revenue.

cls.cnMar 25 11:44 ET

Trending Industry Today: AKESO Leads Losses In Biotechnology Stocks

Moomoo NewsMar 21 01:30 ET

Bull market sentiment? The WuXi group drives the Sector to explode, high position funds are still trapped, and Fund managers predict that the Innovative Drugs market will last throughout the year.

① The WuXi system has driven a significant rise in the pharmaceutical Sector, the Innovative Drugs bull has arrived; ② Feedback from fund investors: the Fund has rebounded, but has not returned to the original investment; ③ Investors are most concerned about whether the market can continue.

cls.cnMar 18 09:46 ET

WuXi AppTec GAAP EPS of RMB3.22, Revenue of RMB39.24B; Initiates 2025 Outlook

Seeking AlphaMar 18 08:37 ET

EXCLUSIVE: Indaptus Therapeutics Starts Phase 1 Combination Study of Decoy20 With BeiGene's Cancer Drug For Advanced Solid Tumors

BenzingaMar 18 07:45 ET

WUXI APPTEC held strong! Achieved 2024 performance guidance, expecting to achieve double-digit growth in revenue this year | Interpretations

In 2024, WUXI APPTEC's revenue and net profit saw a slight decline year-on-year, but it still achieved the performance guidance set at the beginning of last year; Despite the ongoing disturbances from the "Biotechnology Safety Act", customers and Orders still experienced substantial growth in 2024; WUXI APPTEC expects to achieve double-digit growth of 10-15% this year.

cls.cnMar 17 11:44 ET